Sanofi, Regeneron drug cuts cholesterol in nine late-stage trials

July 30, 2014 12:11 PM

20 0

Sanofi, Regeneron drug cuts cholesterol in nine late-stage trials

PARIS (Reuters) - A new drug being developed by French drugmaker Sanofi and U.S. partner Regeneron cut "bad" LDL cholesterol more than placebo and existing treatments in nine late-stage clinical trials, the companies said on Wednesday.

The injectable drug, called alirocumab, is from a promising new class of medicines, called PCSK9 inhibitors, also being developed by Amgen Inc and other drugmakers. If approved, these drugs could reap annual sales of $3 billion or more, according to some industry analysts.

Read more

To category page

Loading...